Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2/3 Study of Masitinib in Combination With Gemcitabine Versus Gemcitabine Alone in Advanced/Metastatic Epithelial Ovarian Cancer Patients in Second Line Being Refractory to First Line Platinum Treatment or in Third Line

NCT02490488 is registered in ClinicalTrials.gov with AB Science as lead sponsor.

NCT NCT02490488
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02490488 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2/3 Study of Masitinib in Combination With Gemcitabine Versus Gemcitabine Alone in Advanced/Metastatic Epithelial Ovarian Cancer Patients in Second Line Being Refractory to First Line Platinum Treatment or in Third Line
Lead sponsor
AB Science
Phase
Phase 2/3
Overall status
Completed
Start date
April 30, 2014
Completion date
December 31, 2020
Enrollment
248 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer